Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 27, 2015 2:08 PM ET


Company Overview of Novo Nordisk, Inc.

Company Overview

Novo Nordisk, Inc. operates as a healthcare company that focuses on diabetes care. The company provides diabetes pharmaceuticals and insulin delivery systems. It also specializes in hemophilia care, growth hormone therapy, and hormone replacement therapy. The company was incorporated in 1982 and is headquartered in Princeton, New Jersey. It has a manufacturing facility in Clayton, North Carolina; and a research and development center in Seattle, Washington. Novo Nordisk, Inc. operates as a subsidiary of Novo Nordisk A/S.

100 College Road West

Princeton, NJ 08540

United States

Founded in 1982





Key Executives for Novo Nordisk, Inc.

Senior Vice President of Finance and Operations
Age: 47
Chief Executive Officer of Novo Nordisk A/S and President of Novo Nordisk A/S
Age: 60
Corporate Vice President and General Counsel
Chief Compliance Officer and Vice President of Compliance
Compensation as of Fiscal Year 2014.

Novo Nordisk, Inc. Key Developments

Novo Nordisk, Inc., Annual General Meeting, Mar 19, 2015

Novo Nordisk, Inc., Annual General Meeting, Mar 19, 2015.

Novo Nordisk, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Novo Nordisk, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Novo Nordisk Announces New Analysis of Phase 3 Data Demonstrating People with Haemophilia A

Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the high annualised bleeding rate (ABR) during initial treatment with NovoEight (turoctocog alfa) showed the large reduction in bleeding over the duration of treatment. The post hoc analysis from the guardian 2 trial further found that, when continued on treatment with NovoEight, adults and adolescents showed reductions of 69% and 63%, respectively, in ABR compared with their ABRs from guardian 1. The guardian 1 trial (along with guardian 3) showed that NovoEight was efficacious in preventing and reducing bleeds with no confirmed inhibitor development in 213 previously treated patients. The most common adverse reactions (=0.5%) seen in the study were injection site reactions, increased hepatic enzymes, and fever.

Similar Private Companies By Industry

Company Name Region
Acenda Pharma, Inc. United States
PharmPro Services United States
Midway Pharmaceuticals Inc. United States
Selexagen Therapeutics, Inc. United States
BioTechnique United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Novo Nordisk, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at